Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zenas BioPharma, Inc.ZBIO · Entity 275 | Director | February 07, 2025 | April 28, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zenas BioPharma, Inc.
Report date February 07, 2025 · Filed April 28, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2025-02-07 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-02-07 · Purchase · Acquired 10,000 · Balance 10,000 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $7.64 to $7.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: This Form 4/A is filed solely to amend the previous Form 4 filed by the Reporting Person on February 11, 2025, which incorrectly reported in column 5 of Table I the amount of securities beneficially owned following reported transactions as 47,000 shares. The correct amount of securities beneficially owned following the reported transactions is 10,000 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $7.64 to $7.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: This Form 4/A is filed solely to amend the previous Form 4 filed by the Reporting Person on February 11, 2025, which incorrectly reported in column 5 of Table I the amount of securities beneficially owned following reported transactions as 47,000 shares. The correct amount of securities beneficially owned following the reported transactions is 10,000 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2025 Filed Feb 11, 2025 16:20 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 10,000 | $7.76 | $77,600.00 |
DisclosureSEC source: 0001104659-25-011505 · tm256174-1_4seq1.xml · nonDerivative · entry 1 Xiao Ting · CIK 0002035283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $7.64 to $7.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| February 07, 2025 Filed Apr 28, 2025 07:07 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 10,000 | $7.76 | $77,600.00 |
DisclosureSEC source: 0001104659-25-039771 · tm2513284-1_4aseq1.xml · nonDerivative · entry 1 Xiao Ting · CIK 0002035283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $7.64 to $7.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · balance_after: This Form 4/A is filed solely to amend the previous Form 4 filed by the Reporting Person on February 11, 2025, which incorrectly reported in column 5 of Table I the amount of securities beneficially owned following reported transactions as 47,000 shares. The correct amount of securities beneficially owned following the reported transactions is 10,000 shares. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 21:03 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100338 · tm2424157-9_4seq1.xml · derivative · entry 1 Xiao Ting · CIK 0002035283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2034-09-11 F1 · derivative.exercise_date: The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.